טוען...
FOXO1 inactivation induces cisplatin resistance in bladder cancer
We found that FOXO1‐shRNA sublines or FOXO1‐positive cells co–treated with a FOXO1 inhibitor were significantly more resistant to cisplatin treatment at pharmacological concentrations, compared with respective control sublines or those with mock treatment. Western blot demonstrated considerable incr...
שמור ב:
| הוצא לאור ב: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7469822/ https://ncbi.nlm.nih.gov/pubmed/32678492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14557 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|